Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 9, 2012, Pages 2990-3011

  Thakker, Rajesh V ^a   Newey, Paul J ^a   Walls, Gerard V ^a   Bilezikian, John ^b   Dralle, Henning ^c   Ebeling, Peter R ^d   Melmed, Shlomo ^e   Sakurai, Akihiro ^f   Tonelli, Francesco ^g   Brandi, Maria Luisa ^g  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Columbia University ^*  (United States)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CALCIMIMETIC AGENT; CALCITRIOL; CIMETIDINE; CISPLATIN; CORTICOSTEROID; DACARBAZINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INDOMETACIN; LANSOPRAZOLE; LITHIUM CARBONATE; METOCLOPRAMIDE; OCTREOTIDE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; SOMATOSTATIN; STREPTOZOCIN; SUNITINIB; VITAMIN D;

ADRENAL CORTEX TUMOR; ADRENAL TUMOR; ARTIFICIAL EMBOLISM; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CLINICAL FEATURE; COLLAGENOMA; DISEASE ASSOCIATION; GASTRINOMA; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GLUCAGONOMA; HEMANGIOFIBROMA; HIGH RISK PATIENT; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; HYPOPARATHYROIDISM; HYPOPHYSIS TUMOR; INSULINOMA; LIPOMA; MEDICAL DECISION MAKING; MENINGIOMA; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 GENE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 GENE; MUTATIONAL ANALYSIS; NEVUS; ONCOGENE; OUTCOME ASSESSMENT; PANCREAS ISLET CELL TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PANCREATICODUODENECTOMY; PARATHYROID TUMOR; PARATHYROIDECTOMY; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOMATIC MUTATION; THYMECTOMY; THYROID TUMOR; TRANSSPHENOIDAL HYPOPHYSECTOMY; VIPOMA; VITAMIN SUPPLEMENTATION;

ADULT; AGED; FEMALE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1;

EID: 84865031294     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1230     Document Type: Review

References (106)

1. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells Jr SA, Marx SJ 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671 (Pubitemid 33152604)
2. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer TT, Varonen H, Vist GE, Williams Jr JW, Zaza S 2004 Grading quality of evidence and strength of recommendations. BMJ 328:1490
3. Swiglo BA, Murad MH, Schünemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM 2008 A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 93:666-673 (Pubitemid 351398536)
4. Thakker RV 2010 Multiple endocrine neoplasia type 1. In: De Groot L, Jameson JL, eds. Endocrinology. 6th ed. Philadelphia: Elsevier; 2719-2741
5. Thakker RV 2011 Multiple endocrine neoplasia type 1 (MEN1). In: Robertson RP, Thakker RV, eds. Translational endocrinology and metabolism. Vol 2. Chevy Chase, MD: The Endocrine Society; 13-44
6. Thakker RV 1998 Multiple endocrine neoplasia - syndromes of the twentieth century. J Clin Endocrinol Metab 83:2617-2620 (Pubitemid 28493749)
7. Machens A, Schaaf L, Karges W, Frank-Raue K, Bartsch DK, Rothmund M, Schneyer U, Goretzki P, Raue F, Dralle H 2007 Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf) 67:613-622 (Pubitemid 47416322)
8. Thomas-Marques L, Murat A, Delemer B, Penfornis A, Cardot-Bauters C, Baudin E, Niccoli-Sire P, Levoir D, Choplin Hdu B, Chabre O, Jovenin N, Cadiot G 2006 Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 101:266-273 (Pubitemid 43381666)
9. Kann PH, Balakina E, Ivan D, Bartsch DK, Meyer S, Klose KJ, Behr T, Langer P 2006 Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer 13:1195-1202 (Pubitemid 46212573)
10. Gibril F, Venzon DJ, Ojeaburu JV, Bashir S, Jensen RT 2001 Prospective study of the natural history of gastrinoma in patients with MEN1:definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 86:5282-5293 (Pubitemid 33070249)
11. Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, Patey M, Mazucca M, Decullier E, Vergès B, Chabre O, Calender A 2008 Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 32:534-543 (Pubitemid 351458295)
12. Vergès B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A 2002 Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87:457-465 (Pubitemid 34158204)
13. Sakurai A, Suzuki S, Kosugi S, Okamoto T, Uchino S, Miya A, Imai T, Kaji H, Komoto I, Miura D, Yamada M, Uruno T, Horiuchi K, Miyauchi A, Imamura M, Fukushima T, Hanazaki K, Hirakawa S, Igarashi T, Iwatani T, Kammori M, Katabami T, Katai M, Kikumori T, Kiribayashi K, Koizumi S, Midorikawa S, Miyabe R, Munekage T, Ozawa A, Shimizu K, Sugitani I, Takeyama H, Yamazaki M 2012 Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database. Clin Endocrinol (Oxf) 76:533-539
14. Asgharian B, Chen YJ, Patronas NJ, Peghini PL, Reynolds JC, Vortmeyer A, Zhuang Z, Venzon DJ, Gibril F, Jensen RT 2004 Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin Cancer Res 10:869-880
15. Flanagan DE, Armitage M, Clein GP, Thakker RV 1996 Prolactinoma presenting in identical twins with multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 45:117-120 (Pubitemid 26248941)
16. Lemos MC, Thakker RV 2008 Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 29:22-32
17. Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P, Niccoli P, Ménégaux F, Chabrier G, Borson-Chazot F, Tabarin A, Bouchard P, Delemer B, Beckers A, Bonithon-Kopp C 2010 Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 34:249-255
18. Geerdink EA, Van der Luijt RB, Lips CJ 2003 Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? Eur J Endocrinol 149:577-582 (Pubitemid 38054703)
19. Dean PG, van Heerden JA, Farley DR, Thompson GB, Grant CS, Harmsen WS, Ilstrup DM 2000 Are patients with multiple endocrine neoplasia type I prone to premature death? World J Surg 24:1437-1441
20. Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells Jr SA, Norton JA 1998 Lethality of multiple endocrine neoplasia type I. World J Surg 22:581-586; discussion 586-587
21. Newey PJ, Thakker RV 2011 Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice. Endocr Pract 17(Suppl 3):8-17
22. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, Goebel SU, Peghini PL, Roy PK, Gibril F, Jensen RT 1999 Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341:635-644 (Pubitemid 29399042)
23. Norton JA, Jensen RT 2007 Role of surgery in Zollinger-Ellison syndrome. J Am Coll Surg 205:S34-S37 (Pubitemid 47488912)
24. Imamura M, Komoto I, Ota S, Hiratsuka T, Kosugi S, Doi R, Awane M, Inoue N 2011 Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 17:1343-1353
25. Tonelli F, Fratini G, Nesi G, Tommasi MS, Batignani G, Falchetti A, Brandi ML 2006 Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 244:61-70 (Pubitemid 44297449)
26. Schreinemakers JM, Pieterman CR, Scholten A, Vriens MR, Valk GD, Rinkes IH 2011 The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J Surg 35:1993-2005
27. Waldmann J, López CL, Langer P, Rothmund M, Bartsch DK 2010 Surgery for multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. Br J Surg 97:1528-1534
28. Akerström G, Hellman P 2007 Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21:87-109 (Pubitemid 46421901)
29. Fernandez A, Karavitaki N, Wass JA 2010 Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72:377-382
30. Eller-Vainicher C, Chiodini I, Battista C, Viti R, Mascia ML, Massironi S, Peracchi M, D'Agruma L, Minisola S, Corbetta S, Cole DE, Spada A, Scillitani A 2009 Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res 24:1404-1410
31. Shih RY, Fackler S, Maturo S, True MW, Brennan J, Wells D 2009 Parathyroid carcinoma in multiple endocrine neoplasia type 1 with a classic germline mutation. Endocr Pract 15:567-572
32. del Pozo C, García-Pascual L, Balsells M, Barahona MJ, Veloso E, González C, Anglada-Barceló J 2011 Parathyroid carcinoma in multiple endocrine neoplasia type 1. Case report and review of the literature. Hormones (Athens) 10:326-331
33. Tonelli F, Marcucci T, Giudici F, Falchetti A, Brandi ML 2009 Surgical approach in hereditary hyperparathyroidism. Endocr J 56:827-841
34. Lambert LA, Shapiro SE, Lee JE, Perrier ND, Truong M, Wallace MJ, Hoff AO, Gagel RF, Evans DB 2005 Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch Surg 140:374-382 (Pubitemid 40489957)
35. Tonelli F, Marcucci T, Fratini G, Tommasi MS, Falchetti A, Brandi ML 2007 Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg 246:1075-1082 (Pubitemid 350179202)
36. Norton JA, Venzon DJ, Berna MJ, Alexander HR, Fraker DL, Libutti SK, Marx SJ, Gibril F, Jensen RT 2008 Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg 247:501-510
37. Moyes VJ, Monson JP, Chew SL, Akker SA 2010 Clinical use of cinacalcet in MEN1 hyperparathyroidism. Int J Endocrinol 2010:906163
38. Anlauf M, Garbrecht N, Henopp T, Schmitt A, Schlenger R, Raffel A, Krausch M, Gimm O, Eisenberger CF, Knoefel WT, Dralle H, Komminoth P, Heitz PU, Perren A, Klöppel G 2006 Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol 12:5440-5446 (Pubitemid 44501800)
39. Dralle H, Krohn SL, Karges W, Boehm BO, Brauckhoff M, Gimm O 2004 Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg 28:1248-1260 (Pubitemid 40941288)
40. Newey PJ, Jeyabalan J, Walls GV, Christie PT, Gleeson FV, Gould S, Johnson PR, Phillips RR, Ryan FJ, Shine B, Bowl MR, Thakker RV 2009 Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 94:3640-3646
41. Triponez F, Dosseh D, Goudet P, Cougard P, Bauters C, Murat A, Cadiot G, Niccoli-Sire P, Chayvialle JA, Calender A, Proye CA 2006 Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 243:265-272 (Pubitemid 43185447)
42. Fendrich V, Langer P, Waldmann J, Bartsch DK, Rothmund M 2007 Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas. Br J Surg 94:1331-1341 (Pubitemid 350144380)
43. Gibril F, Schumann M, Pace A, Jensen RT 2004 Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine 83:43-83 (Pubitemid 38124855)
44. Turner JJ, Wren AM, Jackson JE, Thakker RV, Meeran K 2002 Localization of gastrinomas by selective intra-arterial calcium injection. Clin Endocrinol (Oxf) 57:821-825 (Pubitemid 36963010)
45. Scarsbrook AF, Thakker RV, Wass JA, Gleeson FV, Phillips RR 2006 Multiple endocrine neoplasia: spectrum of radiologic appearances and discussion of a multitechnique imaging approach. Radiographics 26:433-451 (Pubitemid 43515316)
46. You YN, Thompson GB, Young Jr WF, Larson D, Farley DR, Richards M, Grant CS 2007 Pancreatoduodenal surgery in patients with multiple endocrine neoplasia type 1: operative outcomes, long-term function, and quality of life. Surgery 142:829-836; discussion 836.e1
47. Norton JA 2005 Surgical treatment and prognosis of gastrinoma. Best Pract Res Clin Gastroenterol 19:799-805 (Pubitemid 41614124)
48. Cadiot G, Vuagnat A, Doukhan I, Murat A, Bonnaud G, Delemer B, Thiéfin G, Beckers A, Veyrac M, Proye C, Ruszniewski P, Mignon M 1999 Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Etude des Neoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE). Gastroenterology 116:286-293
49. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT 2001 Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 234:495-505; discussion 505-506
50. Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, Edwards CR, Heath DA, Jackson CE, Jansen S, Lips K, Monson JP, O'Halloran D, Sampson J, Shalet SM, Wheeler MH, Zink A, Thakker RV 1996 Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 89:653-669 (Pubitemid 26319017)
51. Fabbri HC, Mello MP, Soardi FC, Esquiaveto-Aun AM, Oliveira DM, Denardi FC, Moura-Neto A, Garmes HM, Baptista MT, Matos PS, Lemos-Marini SH, D'Souza-Li LF, Guerra-Júnior G 2010 Long-term follow-up of an 8-year-old boy with insulinoma as the first manifestation of a familial form of multiple endocrine neoplasia type 1. Arq Bras Endocrinol Metabol 54:754-760
52. Giudici F, Nesi G, Brandi ML, Tonelli F 2012 Surgical management of insulinomas in multiple endocrine neoplasia type 1. Pancreas 41:547-553
53. Langer P, Kann PH, Fendrich V, Richter G, Diehl S, Rothmund M, Bartsch DK 2004 Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg 28:1317-1322 (Pubitemid 40941299)
54. Triponez F, Goudet P, Dosseh D, Cougard P, Bauters C, Murat A, Cadiot G, Niccoli-Sire P, Calender A, Proye CA 2006 Is surgery beneficial for MEN1 patients with small (< or 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 30:654-662; discussion 663-664
55. Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE, Yao JC, Waguespack SG, Gagel RF, Evans DB, Perrier ND 2006 Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 30:643-653 (Pubitemid 43724089)
56. Lowney JK, Frisella MM, Lairmore TC, Doherty GM 1998 Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. Surgery 124:1043-1048, discussion 1048-1049
57. Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M 2005 Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 242:757-764, discussion 764-766
58. Anlauf M, Schlenger R, Perren A, Bauersfeld J, Koch CA, Dralle H, Raffel A, Knoefel WT, Weihe E, Ruszniewski P, Couvelard A, Komminoth P, Heitz PU, Klöppel G 2006 Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 30:560-574 (Pubitemid 44265008)
59. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K 2011 Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523
60. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P 2011 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513
61. Sano T, Yamasaki R, Saito H, Hirose T, Kudo E, Kameyama K, Hiraishi K, Saito S, Hizawa K 1987 Growth hormone-releasing hormone (GHRH)-secreting pancreatic tumor in a patient with multiple endocrine neoplasia type I. Am J Surg Pathol 11:810-819 (Pubitemid 17143587)
62. Melmed S 2011 Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7:257-266
63. Beckers A, Betea D, Valdes Socin H, Stevenaert A 2003 The treatment of sporadic versus MEN1-related pituitary adenomas. J Intern Med 253:599-605 (Pubitemid 36649091)
64. Stratakis CA, Schussheim DH, Freedman SM, Keil MF, Pack SD, Agarwal SK, Skarulis MC, Weil RJ, Lubensky IA, Zhuang Z, Oldfield EH, Marx SJ 2000 Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 85:4776-4780 (Pubitemid 32157665)
65. Burgess JR, Shepherd JJ, Parameswaran V, Hoffman L, Greenaway TM1996 Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. J Clin Endocrinol Metab 81:2642-2646 (Pubitemid 26240291)
66. Elston MS, McDonald KL, Clifton-Bligh RJ, Robinson BG 2009 Familial pituitary tumor syndromes. Nat Rev Endocrinol 5:453-461
67. Burgess JR, Greenaway TM, Shepherd JJ 1998 Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. J Intern Med 243:465-470 (Pubitemid 28312242)
68. Goudet P, Bonithon-Kopp C, Murat A, Ruszniewski P, Niccoli P, Ménégaux F, Chabrier G, Borson-Chazot F, Tabarin A, Bouchard P, Cadiot G, Beckers A, Guilhem I, Chabre O, Caron P, Du Boullay H, Verges B, Cardot-Bauters C 2011 Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines. Eur J Endocrinol 165:97-105
69. Goudet P, Murat A, Cardot-Bauters C, Emy P, Baudin E, du Boullay Choplin H, Chapuis Y, Kraimps JL, Sadoul JL, Tabarin A, Vergès B, Carnaille B, Niccoli-Sire P, Costa A, Calender A 2009 Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J Surg 33:1197-1207
70. Scarsbrook AF, Ganeshan A, Statham J, Thakker RV, Weaver A, Talbot D, Boardman P, Bradley KM, Gleeson FV, Phillips RR 2007 Anatomic and functional imaging of metastatic carcinoid tumors. Radiographics 27:455-477
71. Gibril F, Chen YJ, Schrump DS, Vortmeyer A, Zhuang Z, Lubensky IA, Reynolds JC, Louie A, Entsuah LK, Huang K, Asgharian B, Jensen RT 2003 Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 88:1066-1081 (Pubitemid 36337758)
72. Berna MJ, Annibale B, Marignani M, Luong TV, Corleto V, Pace A, Ito T, Liewehr D, Venzon DJ, Delle Fave G, Bordi C, Jensen RT 2008 A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 93:1582-1591 (Pubitemid 351656492)
73. Oberg K, Jelic S 2008 Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2):ii102-ii103
74. Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L 2000 Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 343:551-554 (Pubitemid 30650750)
75. Gibril F, Reynolds JC, Lubensky IA, Roy PK, Peghini PL, Doppman JL, Jensen RT 2000 Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J Nucl Med 41:1646-1656
76. Gatta-Cherifi B, Chabre O, Murat A, Niccoli P, Cardot-Bauters C, Rohmer V, Young J, Delemer B, Du Boullay H, Verger MF, Kuhn JM, Sadoul JL, Ruszniewski P, Beckers A, Monsaingeon M, Baudin E, Goudet P, Tabarin A 2012 Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database. Eur J Endocrinol 166:269-279
77. Schaefer S, Shipotko M, Meyer S, Ivan D, Klose KJ, Waldmann J, Langer P, Kann PH 2008 Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Eur J Endocrinol 158:699-704 (Pubitemid 351639608)
78. Langer P, Cupisti K, Bartsch DK, Nies C, Goretzki PE, Rothmund M, Röher HD 2002 Adrenal involvement in multiple endocrine neoplasia type 1. World J Surg 26:891-896 (Pubitemid 36920282)
79. Vidal A, Iglesias MJ, Fernández B, Fonseca E, Cordido F 2008 Cutaneous lesions associated to multiple endocrine neoplasia syndrome type 1. J Eur Acad Dermatol Venereol 22:835-838 (Pubitemid 351837118)
80. Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, Buisson N, De Witte K, Salandre J, Lenoir G, Pugeat M, Calender A, Parente F, Quincey D, Gaudray P, De Wit MJ, Lips CJ, Höppener JW, Khodaei S, Grant AL, Weber G, Kytölä S, Teh BT, Farnebo F, Thakker RV 1997 Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 6:1177-1183 (Pubitemid 27308405)
81. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ 1997 Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404-407
82. Tham E, Grandell U, Lindgren E, Toss G, Skogseid B, Nordenskjöld M 2007 Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. J Clin Endocrinol Metab 92:3389-3395 (Pubitemid 47435311)
83. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz Jr LA, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N 2011 DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331:1199-1203
84. Hannan FM, Nesbit MA, Christie PT, Fratter C, Dudley NE, Sadler GP, Thakker RV 2008 Familial isolated primary hyperparathyroidism caused by mutations of the MEN1 gene. Nat Clin Pract Endocrinol Metab 4:53-58 (Pubitemid 350291116)
85. Agarwal SK, Ozawa A, Mateo CM, Marx SJ 2009 The MEN1 gene and pituitary tumours. Horm Res 71(Suppl 2):131-138
86. Olufemi SE, Green JS, Manickam P, Guru SC, Agarwal SK, Kester MB, Dong Q, Burns AL, Spiegel AM, Marx SJ, Collins FS, Chandrasekharappa SC 1998 Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1 Burin) in four kindreds from Newfoundland. Hum Mutat 11:264-269 (Pubitemid 28177866)
87. Hao W, Skarulis MC, Simonds WF, Weinstein LS, Agarwal SK, Mateo C, James-Newton L, Hobbs GR, Gibril F, Jensen RT, Marx SJ 2004 Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J Clin Endocrinol Metab 89:3776-3784 (Pubitemid 39071471)
88. Burgess JR, Nord B, David R, Greenaway TM, Parameswaran V, Larsson C, Shepherd JJ, Teh BT 2000 Phenotype and phenocopy: the relationship between genotype and clinical phenotype in a single large family with multiple endocrine neoplasia type 1 (MEN 1). Clin Endocrinol (Oxf) 53:205-211 (Pubitemid 30643455)
89. Cavaco BM, Domingues R, Bacelar MC, Cardoso H, Barros L, Gomes L, Ruas MM, Agapito A, Garrão A, Pannett AA, Silva JL, Sobrinho LG, Thakker RV, Leite V 2002 Mutational analysis of Portuguese families with multiple endocrine neoplasia type 1 reveals large germline deletions. Clin Endocrinol (Oxf) 56:465-473
90. Turner JJ, Christie PT, Pearce SH, Turnpenny PD, Thakker RV 2010 Diagnostic challenges due to phenocopies: lessons from multiple endocrine neoplasia type 1 (MEN1). Hum Mutat 31:E1089-E1101
91. Belar O, De La Hoz C, Pérez-Nanclares G, Castaño L, Gaztambide S 2012 Novel mutations in MEN1, CDKN1b and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. Clin Endocrinol (Oxf) 76:719-724
92. Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T, Ferolla P, Emy P, Colao A, De Menis E, Lecomte P, Penfornis F, Delemer B, Bertherat J, Wémeau JL, De Herder W, Archambeaud F, Stevenaert A, Calender A, Murat A, Cavagnini F, Beckers A 2006 Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 91:3316-3323 (Pubitemid 44402097)
93. Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montan̈ana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabaté MI, Villa C, Popelier M, Salvatori R, Jennings J, Longás AF, Labarta Aizpún JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A 2010 Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95:E373-E383
94. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gündogdu S, De Menis E, Mäkinen MJ, Launonen V, Karhu A, Aaltonen LA 2006 Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312:1228-1230 (Pubitemid 43801151)
95. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G, Raverot G, Barlier A, De Herder W, Penfornis A, Ciccarelli E, Estour B, Lecomte P, Gatta B, Chabre O, Sabaté MI, Bertagna X, Garcia Basavilbaso N, Stalldecker G, Colao A, Ferolla P, Wémeau JL, Caron P, Sadoul JL, Oneto A, Archambeaud F, Calender A, Sinilnikova O, Montañana CF, Cavagnini F, Hana V, Solano A, Delettieres D, Luccio-Camelo DC, Basso A, Rohmer V, Brue T, Bours V, Teh BT, Beckers A 2007 Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 92:1891-1896 (Pubitemid 46997206)
96. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira Jr A, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M 2008 The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 93:2390-2401 (Pubitemid 351831563)
97. Molatore S, Marinoni I, Lee M, Pulz E, Ambrosio MR, degli Uberti EC, Zatelli MC, Pellegata NS 2010 A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum Mutat 31:E1825-E1835
98. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, Fend F, Graw J, Atkinson MJ 2006 Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 103:15558-15563 (Pubitemid 44625631)
99. Agarwal SK, Mateo CM, Marx SJ 2009 Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 94:1826-1834
100. Skandarajah A, Barlier A, Morlet-Barlat N, Sebag F, Enjalbert A, Conte-Devolx B, Henry JF 2010 Should routine analysis of the MEN1 gene be performed in all patients with primary hyperparathyroidism under 40 years of age? World J Surg 34:1294-1298
101. Langer P, Wild A, Hall A, Celik I, Rothmund M, Bartsch DK 2003 Prevalence of multiple endocrine neoplasia type 1 in young patients with apparently sporadic primary hyperparathyroidism or pancreaticoduodenal endocrine tumours. Br J Surg 90:1599-1603 (Pubitemid 37533180)
102. Skogseid B, Eriksson B, Lundqvist G, Lörelius LE, Rastad J, Wide L, Akerström G, Oberg K 1991 Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab 73:281-287 (Pubitemid 21921870)
103. Sherman SI 2009 Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94:1493-1499
104. Huang J, Gurung B, Wan B, Matkar S, Veniaminova NA, Wan K, Merchant JL, Hua X, Lei M 2012 The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482:542-546
105. McCarthy N 2012 Anticancer drugs: targeting menin. Nat Rev Drug Discov 11:190
106. Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ, Showalter HD, Murai MJ, Belcher AM, Hartley T, Hess JL, Cierpicki T 2012 Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 8:277-284